Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% Premium

Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% Premium

Source: 
Motley Fool
snippet: 

Takeover bids offering a 245% premium over Sorrento Therapeutics's (NASDAQ: SRNE) $1.45 share price last month might seem like a seize-the-day sort of moment. Especially considering Sorrento's financial situation.